Ratings Hamilton Thorne Ltd. Toronto S.E.

Equities

HTL

CA4078911001

Market Closed - Toronto S.E. Other stock markets 03:50:03 2024-04-24 pm EDT			5-day change	1st Jan Change
1.36 ^CAD	0.00%		+0.74%	+2.26%

Mar. 27	Hamilton Thorne's Q4 Profit Falls, Sales Rise; Provides 2024 Outlook	MT
Mar. 27	Hamilton Thorne Brief: 2024 guidance is for a sales range between US$78 and $82 million representing 10-15% organic growth; Q1 guidance is for a sales range of $19.0 to $19.4 million	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the past twelve months, EPS forecast has been revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

With an expected P/E ratio at 45.33 and 34 respectively for both the current and next fiscal years, the company operates with high earnings multiples.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
HAMILTON THORNE LTD.	+2.26%	152M	-
THERMO FISHER SCIENTIFIC	+8.78%	219B	B
DANAHER CORPORATION	+8.24%	187B	B-
INTUITIVE SURGICAL, INC.	+11.16%	134B	B-
BOSTON SCIENTIFIC CORPORATION	+26.12%	101B	A-
SIEMENS HEALTHINEERS AG	+0.30%	62.27B	A-
EDWARDS LIFESCIENCES CORPORATION	+16.21%	52.82B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.63%	47.49B	B+
AGILENT TECHNOLOGIES, INC.	-1.11%	40.79B	A
GE HEALTHCARE TECHNOLOGIES INC.	+12.16%	39.35B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes